Heart-failure exacerbation by saxagliptin called 'real' Clinical Endocrinology News Digital Network DALLAS – The glycemia-lowering drug saxagliptin led to a "real" excess of hospitalizations for heart failure in a 16,000-patient trial designed to examine the drug's cardiovascular safety, but given saxagliptin's overall safety in the study the signal ... |
